CORD-19:3c1f47a07aaf0e393dee9fbd08596a4b9f4f0a03 / 244039-244285 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T1907","span":{"begin":0,"end":246},"obj":"Sentence"},{"id":"T40661","span":{"begin":0,"end":246},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Ertapenem's utility lies in the treatment of community-acquired infections, where ESBL producers are likely or proven; it has convenient, oncedaily, dosing but is the most vulnerable carbapenem to combinations of ESBL or AmpC plus impermeability."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T6","span":{"begin":0,"end":246},"obj":"Sentence"}],"text":"Ertapenem's utility lies in the treatment of community-acquired infections, where ESBL producers are likely or proven; it has convenient, oncedaily, dosing but is the most vulnerable carbapenem to combinations of ESBL or AmpC plus impermeability."}

{"project":"Epistemic_Statements","denotations":[{"id":"T534","span":{"begin":0,"end":246},"obj":"Epistemic_statement"}],"text":"Ertapenem's utility lies in the treatment of community-acquired infections, where ESBL producers are likely or proven; it has convenient, oncedaily, dosing but is the most vulnerable carbapenem to combinations of ESBL or AmpC plus impermeability."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T887","span":{"begin":64,"end":74},"obj":"Disease"},{"id":"T3687","span":{"begin":64,"end":74},"obj":"Disease"}],"attributes":[{"id":"A887","pred":"mondo_id","subj":"T887","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A15905","pred":"mondo_id","subj":"T3687","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Ertapenem's utility lies in the treatment of community-acquired infections, where ESBL producers are likely or proven; it has convenient, oncedaily, dosing but is the most vulnerable carbapenem to combinations of ESBL or AmpC plus impermeability."}